Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06058585 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Study acronym: CAPTIVATE
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 4 months later Aug 30, 2028 → Dec 31, 2029
Primary endpoints added 1 → 3 primary endpoints
See other at-risk trials from The George Institute

Record History

  1. Primary completion pushed from Aug 30, 2028 to Dec 31, 2029 Primary endpoint(s) modified · Enrollment increased: 1000 → 2000 participants · Trial sites expanded: 43 → 51 locations · 6 more Show 9 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment increased: 1000 → 2000 participants
    • Trial sites expanded: 43 → 51 locations
    • Completion pushed from Mar 31, 2029 to Dec 31, 2029
    • Interventions modified
    • Trial arms changed: 2 → 4
    • Eligibility criteria expanded, about 575 words
    • Secondary endpoints: 6 to 22
    • Publications: details revised at 4 of 4 entries
  2. Study sites: 32 to 43v11
  3. Study sites: 31 to 32v10
  4. Study sites: 29 to 31v9
  5. Study sites: 27 to 29v8
Show 6 earlier versionsHide 6 earlier versions
  1. Completion date: Dec 31, 2028 to Mar 31, 2029v7
  2. Study sites: 25 to 27v6
  3. Study sites: 13 to 25v5
  4. Study sites: 1 to 13 Start date changed from estimate of Aug 19, 2024 to Sep 4, 2024 · Interventions: Endothelin Receptor Antagonist (Drug), Finerenone (Drug), Placebo Endothelin Receptor Antagonist (Drug), Placebo Finerenone (Drug) to Finerenone (Drug), Placebo Finerenone (Drug) · Study arms: 4 to 2v4 Show 3 more changesShow less
    • Start date changed from estimate of Aug 19, 2024 to Sep 4, 2024
    • Interventions: Endothelin Receptor Antagonist (Drug), Finerenone (Drug), Placebo Endothelin Receptor Antagonist (Drug), Placebo Finerenone (Drug) to Finerenone (Drug), Placebo Finerenone (Drug)
    • Study arms: 4 to 2
  5. Trial status: Not Yet Recruiting to Recruiting Start date: Jun 15, 2024 to Aug 19, 2024 · Study sites: 0 to 1v3 Show 2 more changesShow less
    • Start date: Jun 15, 2024 to Aug 19, 2024
    • Study sites: 0 to 1
  6. Start date: May 15, 2024 to Jun 15, 2024 Primary completion date: Jun 30, 2028 to Aug 30, 2028 · Interventions: Mineralocorticoid receptor antagonist (Drug), Placebo (Drug) to Endothelin Receptor Antagonist (Drug), Finerenone (Drug), Placebo Endothelin Receptor Antagonist (Drug), Placebo Finerenone (Drug) · Study arms: 2 to 4v2 Show 3 more changesShow less
    • Primary completion date: Jun 30, 2028 to Aug 30, 2028
    • Interventions: Mineralocorticoid receptor antagonist (Drug), Placebo (Drug) to Endothelin Receptor Antagonist (Drug), Finerenone (Drug), Placebo Endothelin Receptor Antagonist (Drug), Placebo Finerenone (Drug)
    • Study arms: 2 to 4
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD). CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure. CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up. CAPTIVATE includes multiple domains examining different therapies for CKD. Participants may enrol in one or more domains and domains will be added and closed over time. The platform operates under a core protocol with each domain described in a domain specific appendix.
Trial Details
NCT Number NCT06058585
Lead Sponsor The George Institute
Conditions Chronic Kidney Diseases
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov